Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAL0114
- Development stage
- Phase 2
- Lead developer
- Shenzhen Salubris Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**SAL0114** is an investigational oral sustained-release fixed-dose combination of deudextromethorphan, a deuterated form of dextromethorphan, and bupropion, developed by Salubris for major depressive disorder and agitation associated with Alzheimer's disease. Deuteration is intended to improve dextromethorphan metabolic stability and reduce formation of potentially adverse metabolites, while bupropion contributes antidepressant pharmacology and increases deudextromethorphan exposure through CYP2D6 inhibition. The product has been studied as a 30 mg/125 mg sustained-release tablet administered orally. ([frontiersin.org](https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1464564/full))
- Other names
- deudextromethorphan + bupropiondeuterated dextromethorphan + bupropion氘右美沙芬 + 安非他酮氘右美沙芬安非他酮
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)SIGMAR1 (Sigma non-opioid intracellular receptor 1)DAT (Dopamine plasma membrane transport protein)Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on SAL0114.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAL0114.